Ticagrelor monotherapy vs ticagrelor plus aspirin in patients with diabetes mellitus undergoing PCI: the TWILIGHT study

Ticagrelor monotherapy vs ticagrelor plus aspirin in patients with diabetes mellitus undergoing PCI: the TWILIGHT study

2020.05.29

Current standard of care for prevention of thrombotic complications in patients undergoing percutaneous coronary intervention (PCI) is dual antiplatelet therapy (DAPT) with ticagrelor and aspirin,...


Ticagrelor monotherapy vs ticagrelor plus aspirin after complex PCI: the TWILIGHT-COMPLEX analysis

Ticagrelor monotherapy vs ticagrelor plus aspirin after complex PCI: the TWILIGHT-COMPLEX analysis

2020.05.25

Ticagrelor monotherapy has been shown to attenuate bleeding complications without increasing ischaemic risk in patients undergoing complex percutaneous coronary intervention (PCI). A recent study has...


Ticagrelor monotherapy benefits post-PCI in ACS patients: TICO trial

Ticagrelor monotherapy benefits post-PCI in ACS patients: TICO trial

2020.05.22

In patients who underwent percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), ticagrelor monotherapy after 3 months of dual antiplatelet therapy (DAPT) was superior at...


FDA approves dapagliflozin for the treatment of HFrEF

FDA approves dapagliflozin for the treatment of HFrEF

2020.05.18

Earlier this month, the US Food and Drug Administration (FDA) approved dapagliflozin for the treatment of heart failure with reduced ejection fraction (HFrEF) in adults with and without type 2...


Baseline renal dysfunction linked to higher mortality in elderly ACS patients undergoing PCI

Baseline renal dysfunction linked to higher mortality in elderly ACS patients undergoing PCI

2020.05.11

Chronic kidney disease is prevalent in patients admitted with acute coronary syndrome (ACS), and becomes more common with increasing age. In this study, researchers sought to assess the impact...


Ethnic differences in the pathobiology of ACS between Asians and Whites

Ethnic differences in the pathobiology of ACS between Asians and Whites

2020.05.04

A study was carried out to ascertain the underlying mechanisms of acute coronary syndromes (ACS) between Asians and Whites.The study population was stratified into ST-elevation myocardial infarction...


Optimal switching strategy from clopidogrel to ticagrelor for Chinese ACS patients managed by PCI

Optimal switching strategy from clopidogrel to ticagrelor for Chinese ACS patients managed by PCI

2020.04.27

In Chinese acute coronary syndrome (ACS) patients with complicated coronary artery disease managed by percutaneous coronary intervention (PCI), the optimal treatment strategy recommended is 180 or 90...


Metformin continuation after primary PCI not associated with increased risk of contrast-induced acute kidney injury

Metformin continuation after primary PCI not associated with increased risk of contrast-induced acute kidney injury

2020.04.20

In patients with diabetes and ST-segment elevation myocardial infarction (STEMI), the continuous use of metformin after primary percutaneous coronary intervention (PCI) remains controversial because...


Efficacy and safety of different ticagrelor regimens vs clopidogrel in CAD patients: the SUPERIOR study

Efficacy and safety of different ticagrelor regimens vs clopidogrel in CAD patients: the SUPERIOR study

2020.04.13

Current guidelines recommend dual antiplatelet therapy with ticagrelor 90 mg twice daily (T90BID) over clopidogrel 75 mg once daily (C75QD) in addition to aspirin for acute coronary syndrome. However...


Prediction of short-term mortality post-PCI using the decision-tree model

Prediction of short-term mortality post-PCI using the decision-tree model

2020.04.06

The decision-tree (DT) model has been shown to be effective in predicting 30-day mortality after percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI).This is based on a...